ISDA

Deposition Date 2015-07-23

Release Date 2015-09-09

Last Version Date 2024-03-06

Entry Detail

PDB ID:

5CT7

Keywords:

TRANSFERASE

Title:

BRAF in Complex with RAF265

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.17 Å

R-Value Free:

0.21

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Serine/threonine-protein kinase B-raf
Gene (Uniprot):BRAF
Chain IDs:A, B
Chain Length:281
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P15056 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

55J

Primary Citation

Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.

Williams, T.E, Subramanian, S, Verhagen, J, McBride, C.M, Costales, A, Sung, L, Antonios-McCrea, W, McKenna, M, Louie, A.K, Ramurthy, S, Levine, B, Shafer, C.M, Machajewski, T, Renhowe, P.A, Appleton, B.A, Amiri, P, Chou, J, Stuart, D, Aardalen, K, Poon, D.Show

Acs Med.Chem.Lett. 6 961 965 (2015)

PMID: 26396681 DOI: 10.1021/ml500526p

Abstact

Abrogation of errant signaling along the MAPK pathway through the inhibition of B-RAF kinase is a validated approach for the treatment of pathway-dependent cancers. We report the development of imidazo-benzimidazoles as potent B-RAF inhibitors. Robust in vivo efficacy coupled with correlating pharmacokinetic/pharmacodynamic (PKPD) and PD-efficacy relationships led to the identification of RAF265, 1, which has advanced into clinical trials.

Legend

Protein

Chemical

Disease

Primary Citation of related structures